6H0E

FAB dmCBTAU-22.1 IN COMPLEX WITH TAU PEPTIDE V1088-23


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.95 Å
  • R-Value Free: 0.285 
  • R-Value Work: 0.222 

wwPDB Validation 3D Report Full Report


This is version 1.0 of the entry. See complete history

Literature

Enhancement of therapeutic potential of a naturally occurring human antibody targeting a phosphorylated Ser422containing epitope on pathological tau.

van Ameijde, J.Crespo, R.Janson, R.Juraszek, J.Siregar, B.Verveen, H.Sprengers, I.Nahar, T.Hoozemans, J.J.Steinbacher, S.Willems, R.Delbroek, L.Borgers, M.Dockx, K.Van Kolen, K.Mercken, M.Pascual, G.Koudstaal, W.Apetri, A.

(2018) Acta Neuropathol Commun 6: 59-59

  • DOI: 10.1186/s40478-018-0562-9
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • Aggregation of tau protein and spreading of tau aggregates are pivotal pathological processes in a range of neurological disorders. Accumulating evidence suggests that immunotherapy targeting tau may be a viable therapeutic strategy. We have previous ...

    Aggregation of tau protein and spreading of tau aggregates are pivotal pathological processes in a range of neurological disorders. Accumulating evidence suggests that immunotherapy targeting tau may be a viable therapeutic strategy. We have previously described the isolation of antibody CBTAU-22.1 from the memory B-cell repertoire of healthy human donors. CBTAU-22.1 was shown to specifically bind a disease-associated phosphorylated epitope in the C-terminus of tau (Ser 422 ) and to be able to inhibit the spreading of pathological tau aggregates from P301S spinal cord lysates in vitro, albeit with limited potency. Using a combination of rational design and random mutagenesis we have derived a variant antibody with improved affinity while maintaining the specificity of the parental antibody. This affinity improved antibody showed greatly enhanced potency in a cell-based immunodepletion assay using paired helical filaments (PHFs) derived from human Alzheimer's disease (AD) brain tissue. Moreover, the affinity improved antibody limits the in vitro aggregation propensity of full length tau species specifically phosphorylated at position 422 produced by employing a native chemical ligation approach. Together, these results indicate that in addition to being able to inhibit the spreading of pathological tau aggregates, the matured antibody can potentially also interfere with the nucleation of tau which is believed to be the first step of the pathogenic process. Finally, the functionality in a P301L transgenic mice co-injection model highlights the therapeutic potential of human antibody dmCBTAU-22.1.


    Organizational Affiliation

    Molecular and Cellular Pharmacology, Discovery Sciences, Janssen Pharmaceutical Companies of Johnson and Johnson, Turnhoutseweg 30, 2340, Beerse, Belgium.,Proteros Biostructures GmbH, Bunsenstra├če 7a, 82152, Planegg, Germany.,Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson and Johnson, Archimedesweg 6, 2333, Leiden, CN, the Netherlands.,Department of Pathology, Amsterdam Neuroscience, VU University Medical Center, De Boelelaan 1117, 1081, HV, Amsterdam, the Netherlands.,Janssen Neuroscience Discovery, Janssen Pharmaceutical Companies of Johnson and Johnson, Turnhoutseweg 30, 2340, Beerse, Belgium.,Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson and Johnson, 3210 Merryfield Row, San Diego, CA, 92121, USA.,Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson and Johnson, Archimedesweg 6, 2333, Leiden, CN, the Netherlands. AApetri@its.jnj.com.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
HUMAN FAB ANTIBODY FRAGMENT OF dmCBTAU-22.1
H, A, C, E
222N/AMutation(s): 0 
Protein Feature View is not available: No corresponding UniProt sequence found.
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetails
HUMAN FAB ANTIBODY FRAGMENT OF dmCBTAU-22.1
L, B, D, F
218N/AMutation(s): 0 
Protein Feature View is not available: No corresponding UniProt sequence found.
Entity ID: 3
MoleculeChainsSequence LengthOrganismDetails
Microtubule-associated protein tau
I, G, J, K
24Mus musculusMutation(s): 0 
Gene Names: Mapt (Mtapt, Tau)
Find proteins for P10637 (Mus musculus)
Go to UniProtKB:  P10637
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
GOL
Query on GOL

Download SDF File 
Download CCD File 
A, B, C, F, H
GLYCEROL
GLYCERIN; PROPANE-1,2,3-TRIOL
C3 H8 O3
PEDCQBHIVMGVHV-UHFFFAOYSA-N
 Ligand Interaction
Modified Residues  2 Unique
IDChainsTypeFormula2D DiagramParent
SEP
Query on SEP
G, I, J, K
L-PEPTIDE LINKINGC3 H8 N O6 PSER
PCA
Query on PCA
A, C, E, H
L-PEPTIDE LINKINGC5 H7 N O3GLU
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.95 Å
  • R-Value Free: 0.285 
  • R-Value Work: 0.222 
  • Space Group: P 1 21 1
Unit Cell:
Length (Å)Angle (°)
a = 107.551α = 90.00
b = 95.502β = 112.64
c = 108.317γ = 90.00
Software Package:
Software NamePurpose
XDSdata reduction
REFMACrefinement
XSCALEdata scaling
MOLREPphasing

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2018-07-25
    Type: Initial release